aSIRTing Control over Cancer Stem Cells
Menée in vitro et in vivo, cette étude montre que, dans les leucémies myélogènes chroniques, l'inhibition de SIRT1 active l'expression de p53 et augmente les effets d'un traitement par imatinib sur les cellules souches cancéreuses
Cancer stem cells lie at the root of chronic myelogenous leukemia (CML) and mediate its continued growth. Their resistance to current therapies results in an inability to eradicate the disease. In this issue of Cancer Cell, Li et al. identify SIRT1 as a new target for eliminating CML cancer stem cells.
Cancer cell , commentaire, 2011